Lantheus Holdings Inc (LNTH) - Total Liabilities

Latest as of December 2025: $1.14 Billion USD

Based on the latest financial reports, Lantheus Holdings Inc (LNTH) has total liabilities worth $1.14 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Lantheus Holdings Inc growing its equity to track the company's year-over-year net asset growth rate.

Lantheus Holdings Inc - Total Liabilities Trend (2012–2025)

This chart illustrates how Lantheus Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See Lantheus Holdings Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Lantheus Holdings Inc Competitors by Total Liabilities

The table below lists competitors of Lantheus Holdings Inc ranked by their total liabilities.

Company Country Total Liabilities
Thai Airways International Public Company Limited
BK:THAI
Thailand ฿227.75 Billion
Choice Hotels International Inc
NYSE:CHH
USA $2.81 Billion
Sinotrans Ltd Class A
SHG:601598
China CN¥34.30 Billion
Arkema SA
PA:AKE
France €7.88 Billion
Sonoco Products Company
NYSE:SON
USA $7.48 Billion
HUB24 Ltd
AU:HUB
Australia AU$132.53 Million
West Fraser Timber Co Ltd
NYSE:WFG
USA $2.04 Billion
Macy’s Inc
NYSE:M
USA $11.38 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Lantheus Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LNTH company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.70 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.04 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.51 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lantheus Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lantheus Holdings Inc (2012–2025)

The table below shows the annual total liabilities of Lantheus Holdings Inc from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 $1.14 Billion +27.49%
2024-12-31 $892.33 Million +6.83%
2023-12-31 $835.26 Million -4.44%
2022-12-31 $874.11 Million +118.89%
2021-12-31 $399.35 Million +12.30%
2020-12-31 $355.62 Million +22.07%
2019-12-31 $291.32 Million -21.02%
2018-12-31 $368.83 Million +2.29%
2017-12-31 $360.57 Million -0.51%
2016-12-31 $362.41 Million -15.26%
2015-12-31 $427.67 Million -12.51%
2014-12-31 $488.84 Million -1.61%
2013-12-31 $496.83 Million -0.19%
2012-12-31 $497.76 Million --

About Lantheus Holdings Inc

NASDAQ:LNTH USA Drug Manufacturers - Specialty & Generic
Market Cap
$6.61 Billion
Market Cap Rank
#3574 Global
#1253 in USA
Share Price
$99.64
Change (1 day)
-1.35%
52-Week Range
$50.11 - $110.94
All Time High
$123.62
About

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more